

Substance P and the Neurokinins: Novel Peptide Neurotransmitters in Psychopharmacology

Stephen M. Stahl, M.D., Ph.D.

Issue: *A new neurotransmitter system is a family of 3 related peptides known as neurokinins. The best known of these is substance P. The others are known simply as neurokinin A and neurokinin B. The specific receptor subtypes that correspond to these 3 neurokinins are neurokinin 1 receptors for substance P, neurokinin 2 receptors for neurokinin A, and neurokinin 3 receptors for neurokinin B. These neurotransmitters appear to play a key role in the regulation of emotions, and antagonists of their receptors may be novel psychotropic drugs of the future.*

T

his month's feature is the second of a 3-part series on peptides and psychiatry. Part 1 appeared last month as a visual lesson on neuropeptide neurotransmitter synthesis, storage, and release in the central nervous system.¹ Part 2 is presented here and explores a specific family of neuropeptides and their receptors, known as neurokinins, of which substance P is the best known example.²⁻⁴ Part 3 will appear in the March 1999 BRAINSTORMS and will review interesting developments with substance P antagonists as novel antidepressants in a feature entitled "Substance P and Serendipity: Novel Psychotropics Are a Possibility."

Take-Home Points

- ◆ Substance P is a member of a family of related peptides originally known as tachykinins because they are rapid-acting, but are now called neurokinins (NKs)
- ◆ The names for the precursors, neurotransmitters, and receptors within the same family are confusing. For the clinician, it is worth knowing 3 neurotransmitters and 3 receptors for the tachykinin family: Substance P is the neurokinin neurotransmitter that selectively binds to NK-1 receptors; NK-A selectively binds to NK-2 receptors; and NK-B selectively binds to NK-3 receptors


REFERENCES

1. Stahl SM. Peptides and psychiatry, part 1: how synthesis of neuropeptides differs from classical neurotransmitter synthesis. *J Clin Psychiatry* 1999;1:5-6
2. Feldman RS, Meyer JS, Quenzer LF. *Principles of Neuropsychopharmacology*. Sunderland, Mass: Sinauer Assoc; 1997
3. Otsuka M, Yoshioka IC. Neurotransmitter functions of mammalian tachykinins. *Physiol Rev* 1993;73:229-308
4. Cooper JF, Bloom FE, Roth RH. *The Biochemical Basis of Neuropharmacology*. New York, NY: Oxford University Press; 1996


BRAINSTORMS is a monthly section of The Journal of Clinical Psychiatry aimed at providing updates of novel concepts emerging from the neurosciences that have relevance to the practicing psychiatrist.

From the Clinical Neuroscience Research Center in San Diego and the Department of Psychiatry at the University of California San Diego.


Reprint requests to: Stephen M. Stahl, M.D., Ph.D., Editor, BRAINSTORMS, 8899 University Center Lane, Suite 130, San Diego, CA 92122.



Substance P can be synthesized from only 1 gene, but from 3 different forms of alternatively spliced mRNA: alpha, beta, and gamma.²⁻⁴ The gene is called PPT-A for preprotachykinin A. Here, substance P is being synthesized from the α -PPT-A form of mRNA. Substance P is eventually formed when α -PPT-A protein is cleaved twice: first to α -PT-A (protachykinin) by a signal peptidase enzyme and then further to substance P itself by a converting enzyme. Once substance P is released, it interacts selectively with neurokinin 1 (NK-1) receptors.



Both substance P and NK-A can be synthesized from 2 types of mRNA derived from the PPT-A gene, namely the beta and gamma forms of PPT-A mRNA.²⁻⁴ Figure 2 shows the creation of substance P and NK-A from the β -PPT-A type of mRNA. Not shown is the analogous process for creating these same 2 peptides from the γ -PPT-A type of mRNA. The conversion of these 2 forms of mRNA into substance P or NK-A occurs by the same processes outlined in Figure 1. Once released, substance P will interact with NK-1 receptors, but NK-A will interact with NK-2 receptors.



Finally, NK-B is formed from a different gene called PPT-B, which is transcribed to PPT-B mRNA, translated to PPT-B protein, and eventually cleaved into NK-B, which can interact with NK-3 receptors.²⁻⁴